Earnings Feed
Start Free
Allogene Therapeutics, Inc.·4

Mar 18, 4:05 PM ET

Chang David D 4

Research Summary

AI-generated summary

Updated

Allogene (ALLO) CEO David Chang Sells 47,763 Shares

What Happened
David D. Chang, President, CEO and a director of Allogene Therapeutics (ALLO), sold 47,763 shares of Allogene common stock on March 16, 2026 at $2.47 per share for proceeds of $117,975. The filing reports this was a sale (S) and is characterized as a sell-to-cover to satisfy tax withholding on vested restricted stock units, not a discretionary open-market divestiture.

Key Details

  • Transaction date: 2026-03-16; Sale price: $2.47 per share; Total proceeds: $117,975.
  • Filing date / accession: Form 4 filed 2026-03-18 (timely filed within SEC rules).
  • Shares owned after the transaction: Not specified in the filing.
  • Notable footnotes:
    • F1: Sale mandated to cover tax withholding on RSU vesting (sell-to-cover), not a discretionary trade.
    • F2: Filing notes Chang acquired 12,500 shares on Mar 15, 2026 via the employee stock purchase program.
    • F3–F5: Additional shares are held in various trusts (RTC 2019, JEC 2019, Chang 2006 Family Trust).

Context
This was a routine sell-to-cover transaction to satisfy tax obligations on vested awards and does not necessarily signal the insider’s view on the company’s prospects. Purchases generally provide stronger evidence of insider confidence; this filing documents a tax-related sale.